CROSSJECT (ALCJ.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ALCJ - FR0011716265 - Common Stock
ALCJ.PA Key Statistics, Chart & Performance
The current stock price of ALCJ.PA is 1.97 EUR. In the past month the price decreased by -10.45%. In the past year, price decreased by -3.9%.
ALCJ.PA Technical Analysis
ALCJ.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALCJ.PA. ALCJ.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
ALCJ.PA Financial Highlights
Over the last trailing twelve months ALCJ.PA reported a non-GAAP Earnings per Share(EPS) of -0.23. The EPS increased by 13.8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.89% | ||
| ROE | -308.38% | ||
| Debt/Equity | 2.52 |
ALCJ.PA Forecast & Estimates
9 analysts have analysed ALCJ.PA and the average price target is 3.88 EUR. This implies a price increase of 96.75% is expected in the next year compared to the current price of 1.97.
For the next year, analysts expect an EPS growth of 135.12% and a revenue growth 428.6% for ALCJ.PA
ALCJ.PA Ownership
About ALCJ.PA
Company Profile
Crossject SA manufactures and markets needle free injection system. The company is headquartered in Dijon, Bourgogne-Franche-Comte and currently employs 103 full-time employees. The company went IPO on 2014-02-20. The firm specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous, and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The firm's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance, and comfort. The firm has industrial partnerships with Hirtenberger and Recipharm. The company provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.
Company Info
CROSSJECT
Parc Mazen-Sully, 6 Rue Pauline Kergomard
Dijon BOURGOGNE-FRANCHE-COMTE FR
Employees: 106
Phone: 33380549850
CROSSJECT / ALCJ.PA FAQ
What does ALCJ do?
Crossject SA manufactures and markets needle free injection system. The company is headquartered in Dijon, Bourgogne-Franche-Comte and currently employs 103 full-time employees. The company went IPO on 2014-02-20. The firm specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous, and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The firm's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance, and comfort. The firm has industrial partnerships with Hirtenberger and Recipharm. The company provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.
Can you provide the latest stock price for CROSSJECT?
The current stock price of ALCJ.PA is 1.97 EUR. The price decreased by -5.74% in the last trading session.
Does ALCJ stock pay dividends?
ALCJ.PA does not pay a dividend.
What is the ChartMill rating of CROSSJECT stock?
ALCJ.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Should I buy ALCJ stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALCJ.PA.
What is the ownership structure of CROSSJECT (ALCJ.PA)?
You can find the ownership structure of CROSSJECT (ALCJ.PA) on the Ownership tab.